Korean J Gynecol Oncol Colposc.
1993 Sep;4(3):63-70.
Hematologic Monitoring in Chemotherapy for Patients with Gynecologic Cancer
Abstract
- A retrogpective review of hematologic rnonitoring involving aggressive chemotherapy was careiyd out ta assese whetber there ia a predictable relatiorship between the white blood ce11 count end the platelet count as a refleetion of bone marrow toxicity and when maximum myeloauppression occur during a treatment program. This data revealed that the white blood cell and granulocyte levels are closely related and that myeloeuppression can oceur during any course of CAP(cyclophosphamide, adriamycin, and cisplatin), VBP(vinblastine, bleomycin, and cisplatin) chemotherspy in gynecological cancer. Thus, for these treatment regimena in gynecoldgical malignancies, the white blood cell and granulocyte count is sufficient for momtoing toxicity and adjusting future courses of chemotherapy. There are no bone merrow depresaions by the treatment regirnens for the gestational trophoblastic disease.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Clinical Analysis of Hematologic Monitoring in Chemotherapy for Patients with Gynecologic Cancer
- Amifostine Pretreatment for Protection against Cisplatin-based Combination Chemotherapy in Gynecologic Cancer Patients
- Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer
- Assessment and research of quality of life in gynecologic cancer patients
- Hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer
